RVMD
Revolution Medicines, Inc. Health Care Biological Products, (No Diagnostic Substances) Russell 3000
$191.31Close
$37.7BMarket cap
$58.57 – $221.1552-week range
Nov 4, 2026Next report · after the close
Highlights
Strengths
- Leading the market RS 97 · stronger than 97% of stocks over 12 months
Cautions
- Trend not confirmed 7 of 8 conditions · under the 50-day
- Results soon Nov 4, 2026, in 3 days
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
13%
1wk
up 2.3%
price change
1mo
down 6.8%
price change
12-month return
up 225%
market up 11% ·
its own up 219%
F-score
—
— Not assessed
Altman Z
28.81
Low risk
P/E
—
price / earnings
PEG
—
P/E / EPS growth
P/B
23.1×
price / book
Earnings yield
down 3.2%
EBIT / enterprise value
Cheaper than
13%
of the market · expensive
Revenue growth
—
year on year
EPS growth
—
latest quarter
Sales growth
—
latest quarter
ROE
down 58%
return on equity
Free cash margin
—
-$913.7M FCF
D/E
—
long-term debt / equity
Net debt / EBITDA
—
Interest cover
—EBIT / interest
Trade setup
ATR%
4.2%
$8.13 a day · 2×ATR $175.06
RS
97 / 99
vs the universe
Trend
7 / 8
under the 50-day
Relative volume
0.5×
vs 50-day average
Up/down volume
1.10
50 sessions
Implied move
—
no option chain · report Nov 4, 2026
Trend template · 7 of 8
- Price above the 50-day average: fails
Screen verdict
Did not qualify for any screen.
Warning signs
- Shareholders diluted The share count rose 6.0% over the year, from 186m to 197m shares. Each existing share owns a smaller fraction of the company than it did a year ago.
Last reported
Aug 5, 2026
Results reaction
Aug 5, 2026+3% vs market2 sessions after results
Financials
- Net
- Free cash
- Cash
- Long-term debt
| FY2020Dec 31, 2020 | FY2021Dec 31, 2021 | FY2022Dec 31, 2022 | FY2023Dec 31, 2023 | FY2024Dec 31, 2024 | FY2025Dec 31, 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $43.0M | $29.4M | $35.4M | $11.6M | $0 | $0 |
| Operating income | -$110.7M | -$188.0M | -$258.3M | -$487.2M | -$689.5M | -$1.2B |
| Net income | -$108.2M | -$187.0M | -$249.0M | -$436.0M | -$600.0M | -$1.1B |
| Net margin | -252% | -636% | -704% | -3765% | — | — |
| Earnings per share | -$1.97 | -$2.57 | -$3.09 | -$3.85 | -$3.58 | -$5.95 |
| Free cash flow | -$103.0M | -$153.7M | -$235.2M | -$358.3M | -$567.7M | -$913.7M |
| Free cash margin | -240% | -523% | -665% | -3094% | — | — |
| Cash | $104.3M | $108.5M | $161.4M | $696.1M | $543.1M | $383.7M |
| Shareholders' equity | $474.7M | $602.6M | $685.2M | $1.8B | $2.3B | $1.6B |
| Shares outstanding | 66.60m | 74.14m | 90.41m | 164.67m | 185.90m | 197m |
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Aug 5, 2026 | Quarterly ↗ | Jun 30, 2026 | 36d |
| May 6, 2026 | Quarterly ↗ | Mar 31, 2026 | 36d |
| Feb 25, 2026 | Annual ↗ | Dec 31, 2025 | 56d |
| Nov 5, 2025 | Quarterly ↗ | Sep 30, 2025 | 36d |
| Aug 6, 2025 | Quarterly ↗ | Jun 30, 2025 | 37d |
| May 7, 2025 | Quarterly ↗ | Mar 31, 2025 | 37d |
| Feb 26, 2025 | Annual ↗ | Dec 31, 2024 | 57d |
| Nov 6, 2024 | Quarterly ↗ | Sep 30, 2024 | 37d |
| Aug 7, 2024 | Quarterly ↗ | Jun 30, 2024 | 38d |
| May 8, 2024 | Quarterly ↗ | Mar 31, 2024 | 38d |
| Feb 26, 2024 | Annual ↗ | Dec 31, 2023 | 57d |
| Nov 6, 2023 | Quarterly ↗ | Sep 30, 2023 | 37d |
Current reports
| Filed | Disclosed |
|---|---|
| Oct 13, 2026 | New obligation · Other events ↗ |
| Sep 1, 2026 | Material agreement · New obligation ↗ |
| Aug 26, 2026 | Other events ↗ |
| Aug 5, 2026 | Results ↗ |
| Jun 22, 2026 | Director or officer change · Shareholder vote ↗ |
| May 6, 2026 | Results ↗ |
| Apr 17, 2026 | Material agreement · New obligation · Other events ↗ |
| Apr 16, 2026 | Other events ↗ |
| Apr 13, 2026 | Other events ↗ |
| Feb 25, 2026 | Results ↗ |
| Nov 5, 2025 | Results ↗ |
| Oct 17, 2025 | Other events ↗ |